Pink SheetAlyftrek (vanzacaftor/tezacaftor/deutivacaftor), Vertex Pharmaceuticals’ next generation treatment for cystic fibrosis (CF) is one of six orphan products that the European Medicines Agency backed for
ScripAkeso has garnered a regulatory nod for penpulimab from the US Food and Drug Administration, making the agent the second PD-1 checkpoint inhibitor originating from a Chinese drug maker in the US marke
ScripResults from a Phase III study in China of Akeso and Summit Therapeutics’ ivonescimab in non-small cell lung cancer (NSCLC) are an encouraging sign for the PD-1/VEGF-targeting bispecific antibody’s pi
ScripThe number of drug candidates in the pipeline in 2024 rose by its lowest rate so far this decade, with the total at the turn of the year hitting 23,875. The 4.60% increase over 2024’s pipeline figure